InnovaDerma Investor PresentationLondonOctober 2016

Legal Disclaimer

These presentation materials (the “Materials”) do not constitute an offer or invitation to purchase or subscribe for any securities of InnovaDerma plc(the "Company") and should not be relied on in connection with a decision to purchase or subscribe for any such securities. The Materials and theaccompanying oral presentation do not constitute a recommendation regarding any decision to sell or purchase securities in the Company.

The Materials and the accompanying oral presentation are confidential and the Materials are being supplied to you solely for your information andmay not be copied, reproduced or distributed to any other person or published, in whole or in part, for any purpose. No reliance may be placed forany purpose whatsoever on the information contained in the Materials and the accompanying oral presentation or the completeness or accuracy ofsuch information. No representation or warranty, express or implied, is given by or on behalf of the Company, shareholders, directors, officers oremployees or any other person as to the accuracy or completeness of the information or opinions contained in the Materials and the accompanyingoral presentation, and no liability is accepted for any such information or opinions (including in the case of negligence, but excluding any liability forfraud).

The Materials contain forward-looking statements, which relate, inter alia, to the Company’s proposed strategy, plans and objectives. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the control of the Company that could causethe actual performance or achievements of the Company to be materially different from such forward-looking statements. Accordingly, you shouldnot rely on any forward-looking statements and the Company accepts no obligation to disseminate any updates or revisions to such forward-lookingstatements.

The Materials and their contents are directed only at persons who fall within the exemptions contained in certain articles of the Financial Services andMarkets Act 2000 (Financial Promotion) Order 2005 (being persons who are authorised or exempt persons within the meaning of the FinancialServices and Markets Act 2000 and certain other persons having professional experience relating to investments, high net worth companies,unincorporated associations or partnerships and the trustees of high value trusts) and persons to whom distribution may otherwise lawfully be made.Any investment, investment activity or controlled activity to which the Materials relate is available only to such persons and will be engaged in onlywith such persons. Persons of any other description, including those that do not have professional experience in matters relating to investments,should not rely or act upon the Materials.

The Materials are being made available to less than 150 persons excluding persons who are qualified investors (as specified in The ProspectusRegulations 2011 (2011/1668)). A person may qualify as a qualified investor if it is authorised or regulated to operate in the financial markets, itscorporate purpose is solely to invest in securities, it is entered on the register of qualified investors maintained by the relevant prescribed regulatoryauthority or it is a legal entity which has two or more of (i) an average of at least 250 employees during the last financial year; (ii) a total balance sheetof more than €43,000,000; and (iii) an annual turnover of more than €50,000,000 as shown in its last annual or consolidated accounts. [Any recipientof the Materials in the European Union will be deemed to have represented, acknowledged and agreed that it is a qualified investor unless it notifiesthe Company otherwise at the time of receipt.]

The Materials should not be distributed, published, reproduced or otherwise made available in whole or in part by recipients to any other person and,in particular, should not be distributed to persons with an address in the United States of America, Australia, the Republic of South Africa, Japan orCanada or in any other country outside the United Kingdom where such distribution may lead to a breach of any legal or regulatory requirement.

None of Hybridan LLP (“Hybridan”) nor their respective members, directors, officers, employees, agents, affiliates or representatives or advisers norany other person accepts any obligation or responsibility to advise any person of changes in the information set forth herein after the date hereof.Further, Hybridan has not authorised the contents of, or any part of, this document. To the fullest extent permitted by law, none of Hybridan (northeir respective members, directors, officers, employees, agents or representatives) nor any other person accepts any liability whatsoever for anyerrors, omissions or inaccuracies in such information or opinions or for any loss, cost or damage suffered or incurred howsoever arising, directly orindirectly, from any use of this document or its contents or otherwise in connection with the subject matter of this document or any transaction. Thecontents of this Presentation are not to be construed as legal, financial or tax advice. This document should not be distributed in whole or in part toother parties.

2

• Company Description 4

• Investment Proposition 5

• Management Team & Board 6

• Our Products and Product Development 8

• UK Manufacturing and EBITDA 12

• Marketing Investment Strategies 13

• Global Supply Chain 14

• Strongly Positioned for Growth 15

• Summary Financials 16

• Key Milestones 18

• Concluding Remarks 19

3

Contents

Pages

• InnovaDerma develops and distributes clinically proven hair-loss, hair care, self-tanning and skin rejuvenation products internationally in the fast growing “at home” market:

• LEIMO brand distribution, specialising in hair care and hair-loss products were acquired on 31 August 2013:

• The LEIMO products were all developed by PROS International Company Limited, a Korean company

• All the IP for LEIMO was acquired by InnovaDerma from PROS on 23 July 2014

• SKINNY TAN (the world’s first all natural self tan product) acquired on 1 June 2015:

• The SKINNY TAN product range has since been expanded to include 10 new products

• Distribution expanded from 250 stores to 2800 stores in four continents and growing

• Listed on Euronext Marché Libre in May 2015 & on LSE in September 2016

• Proven ability to grow revenue and EBITDA, develop brand portfolio and brand extensions, secure distribution contracts, and scale the business

4

Company Description

• Portfolio of established products and track record in innovation

• Low cost and scalable business model, competitive pricing, protected IP, strong branding and global reach

• Track record of securing contracts with retailers, distributors and partners across four continents which underpin the growthmodel, future acquisition targets and ability to extend brands:

• Highly successful distribution agreement with Superdrug now ranged in all 776 stores

• Olive Young distribution in Korea to more than 600 stores

• Retail distribution agreement with Chemist Warehouse, one of the largest pharmacy chains in Australia

• US retail distribution agreements signed

• Seeking to expand distribution and e-tailer network in existing and new territories

• Strong management team and Board with an international and global track record of successfully growing businesses and creating value

5

Investment Proposition

6

Management Team & Board

Founder & Executive Chairman - Haris Chaudhry

Haris’ career spans 18 years with significant experience creating growth for public & privatecompanies globally. Haris has worked as Director for Global Partnerships & Business Development forCarbon Planet Limited (a Public company), a world leader in carbon economy with emissionsreductions projects around the globe. Haris also worked for Rocksoft Limited (a Public Company) asDirector for Asia-Pacific where he set up business distribution and channel distribution partnersthroughout Asia-Pacific and in Europe, and in Senior Business Development roles with Upstream, afully owned subsidiary of Fuji-Xerox Australia. Haris is Fellow of Australian Institute of Managementand a member of Australian Institute of Company Directors. Haris has in-depth experience in settingup channels and distribution networks in Asia-Pacific, Europe and Americas. He is a provenentrepreneur with public and private companies and experienced in delivering on growth potentialand opportunities. Haris lives in Melbourne.

Executive Director/Finance Director - Joe Bayer

Joe has over 3 decades of executive experience gained in healthcare, pharmacy, consumer products,M&A and capital raising. He has worked globally in senior executive roles for some of the largestconsumer and healthcare companies including CSR, Faulding, Mayne Health and Fletchers. Joe alsoserved as Chairman for Cynergy Health (Australia) for 2 years and is Principal of Cygenta Capital &Advisory. Until recently he was Chief Executive Officer for Kain Corporate & Commercial Lawyers. Joeis a Fellow of CPA Australia and a Graduate of the Australian Institute of Company Directors and livesin Adelaide.

6

Management Team & Board

7

Non Executive Director - Garry G Lemair

Garry is a former President/ CEO of Fortune 500 companies with a 40 year leadership career. Heserved as Senior Vice President & Director for Citibank for Asia, Board member for Diners ClubInternational, CEO & Regional Director for Pepsi Co/ KFC, President Asia Pacific for Fluor Daniels,Managing Director Asia-Pacific for Taubmans/ Courtaulds, President Asia-Pacific for TRS Staffing andas an Interim CEO and Director for a JV created by Westpac, CBA and ANZ banks. He is a Boardmember of Adcorp Australia Ltd and Mariner Corporation Ltd and is a Chairman of LemairInternational, Grenada International and Webprofits Pty Ltd and Telegate Pty Ltd. Garry is a Fellow ofAustralian Institute of Company Directors. Gary lives in Sydney.

Non Executive Director – Rodney Turner

Rodney has been Head of Regulatory & Clinical Affairs and Compliance for some of the largestpharmaceutical companies globally. He currently serves as Head of ANZ Regulatory Affairs for SandozPty Ltd (one of the largest global Pharmaceutical companies) and worked previously with iNovaPharmaceuticals, Valeant Pharmaceuticals, Ventracor, Gambro & Fresenius-Kabi Australia. Rodney is aGraduate of Australian Institute of Company Directors. Rodney lives in Sydney.

Non Executive Director – Clifford Giles

Clifford Giles is a Founder & Managing Director of IPO Capital Partners Ltd (IPO Capital), a pre-IPOinvestment firm based in London. Clifford’s background is in financial services focused on equitymarkets, and his strengths lie in capital raising for small and medium enterprises. Highlights from hiscareer include executive and leadership roles with Reed Business Publishing, Asia Pacific. Founder ofimove, a developer of web-based change of address applications for publishing houses and othermass mailers, listing the company in 2001. Founder of SportsCredit, a financial product enabling eliteathletes to borrow against their on-field contracts to accelerate wealth aspiration. Clifford lives inLondon.

7

8

• The World’s first hair re-growth device, a hand held laser comb using Laser and LED to prevent the progression and recurrence of hair thinning conditions by slowing down the build-up of Dihydrotestosterone (DHT) in the scalp

• Clinically proven device showing 92% success rate in stopping hair loss & re-growing hair in independent clinical studies

Refer to : http://www.innovaderma.com/pdf/LeimoClinicalTrials.pdf

• Approved by KFDA (Korean Food & Drug Agency), listed with TGA (Therapeutic Goods Administration of Australia) & New Zealand Ministry of Health to treat hair loss

• IP protected with Patents in Australia, USA, Europe, Russia, Japan and Korea

• Recurring revenues generated through Leimo® hair and scalp care products

• Highly specialized formulation and manufactured with natural ingredients

• “Leimo For Her” is world’s first device specifically designed for female hair loss market, targeting 35% of females that lose hair in their lifetime

Our Products

9

Product Development

Launch of Laser & LED ‘Headmaster’ Helmet expected after FDA approval in 2017

• The world’s first self-tanner that combines a natural tanning active with naturally derived skin smoothing actives to tan, contour and reduce the visible appearance of cellulite

• Distribution through leading retailers throughout the UK, USA, Australia, Korea and South Africa

• High-profile social media presence on Facebook and Instagram

• Newly developed Professional Salon-only range

• Proven product: UK Celebrity endorsement with independent studies showing almost 90% of Skinny Tan users believed that using the product made them look slimmer

10

Our Products

11

Product Development

• Development of Skinny Tan Professional Range products aimed at beauty & tanning salons finalised

• Diversifies revenue stream with specific products for the professional end users at a higher price point

• An additional eight new retail products under development (10 already developed) for launching in the near future

12

UK Manufacturing and EBITDA

• Following ongoing expansion plans in the UK and Europe and Skinny Tan’s success in the UK, InnovaDerma will be moving a significant part of its production to the UK, from Australia

• Prestige Personal Care appointed to manufacture InnovaDerma’s products. Initially to be distributed to the UK market but with plans to extend to other global markets

• Significant improvement in gross margins as new UK manufacturing strategy integrates from December

• Compared to current costs for manufacturing in Australia, the new costs for goods manufactured will be notably less, coupled with lower overseas freight and distribution costs. Improved margins to flow through second half of FY17

• Improved supply chain initiatives will drive greater efficiencies and significantly improve customer service

Marketing Investment Strategies • Skinny Tan’s social media presence has contributed to the growth in

revenue

• Averaged in excess of 3 to 1 return in revenue for each AUD 1 invested in advertising

• Spend increased from under AUD 90,000 per month in the period to 30 June 2015 to over AUD 175,000 in the period to 31 December 2015

• Strategy is to position marketing spend away from traditional mainstream media and focus on social media where we generate superior returns and ‘own’ the client base

• Our Facebook and Instagram followers drive visibility and sales through third party endorsement. Fastest growing community globally on Facebook & Instagram in this category

• Ongoing project to data mine our online community to enhance further opportunities

13

£0

£200,000

£400,000

£600,000

£800,000

£1,000,000

Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun

SALES REVENUE COMPARISON2O14-2016

2014 2015 2016

£0

£100

£200

£300

£400

£500

£600

£700

£800

£900

Revenue by month forJul2015 – Jun2016 (£'000)

• Fast growing distribution and retail channels across four continents

• Leveraging Skinny Tan opens up access to global supply chain for whole Group

• Current distribution with retailers includes Woolworths, Priceline, Chemist Warehouse and Target in Australia, Superdrug in UK, South Africa’s fastest growing pharmacy Dis-Chem, and Korea’s largest beauty & health chain Olive Young

• Seeking to expand distribution and e-tailer network in existing and new territories including the US and East Asia

• Significant expansion plan in the US underway – increasing our exposure and presence in this large market

RETAILERS GEOGRAPHIC DISTRIBUTION

14

Global Supply Chain

US Expansion planAustralia

New Zealand

South Africa

Spain

UKIreland

Korea

Russia

15

Strongly Positioned for Growth

Self tanning industry – Skinny Tan

• Self tanning industry in the US estimated to be worth US$300m in 20151

• Independent studies in UK showed more than 90% users of Skinny Tan believed that using the product made them look slimmer thus appealing to a wider group of end users

• Significant growth opportunities expected in the US market

• Continue expansion opportunities throughout Europe building on the strong Superdrug performance in the UK

• Building impetus in Asia through South Korea’s Olive Young and further expansion into East Asia

• Consolidate in the Australian/NZ market through leading pharmacy groups and mainstream retailers

• New product development and brand extension strategy accelerating brand breadth and depth.

1IBIS market research (2015)

Hair loss industry – Leimo

• Hair care and Hair loss market estimated to be worth US$20bn and expected to grow at 5% per annum

• US Hair care and Hair loss market estimated at US$7 billion with 35 million US men and 21 million US women experiencing hair loss, respectively

• Leading edge, new generation of topical products and hair loss devices with ‘Headmaster’ helmet to be developed in the US

• Untapped market for hair loss in females as currently male dominated

• InnovaDerma’s female hair loss treatment program (LeimoFor Her) has been developed to target female market

15

16

Profit & Loss Account

From 19 September 2014 to 30 June 2015

From 1 July 2014 to 31 December 2014

From 26 August 2013 to 30 June 2014

(Audited) (Audited) (Audited)

(000) (000) (000)

Revenue £519 £236 £363

Cost of Sales (£171) (£75) (£108)

Gross Profit £348 £161 £254

Marketing expenses (£421) (£150) (£112)

Administrative expenses (£214) (£119) (£139)

Other expenses (£159) (£2) (£8)

Operating profit/(loss) (£446) (£110) (£4)

EBITDA (£446) (£110) (£4)

- -

Tax expense £0 £0 £0

Net profit/(loss) for the period attributable to members of the Company

(£446) (£110) (£4)

Other comprehensive income (£4) - -

Total comprehensive loss for the period attributable to members of the Company

(£450) (£110) (£4)

17

Balance Sheet

As at 30 June 2015 As at 31 December 2014 As at 30 June 2014

(Audited) (Audited) (Audited)

(000) (000) (000)

Current assets

Cash and cash equivalents £105 £432 £21

Trade and other receivables £56 £53 £11

Inventory £169 £112 £56

Other assets £34 £13 £0

Total current assets £364 £610 £88

Non-current assets

Intangible assets £460 £189 £189

Other assets £10 £1 £0

Total non-current assets £470 £190 £189

Total Assets £834 £800 £277

Current liabilities

Trade and other payables £390 £205 £50

Borrowings £341 £703 £231

Total current liabilities £731 £908 £281

Total non-current liabilities £737

Total liabilities £731 £1,645 £281

Net assets £103 (£845) (£4)

Equity

Share Capital £1,229 (£738) £0

Share Premium, Foreign exchange & Merger Reserve

(£651) £0 £0

Accumulated losses (£475) (£107) (£4)

Total equity and reserves £103 (£845) (£4)

2016

February 2016Skinny Tan launched in Superdrug. Now available in all stores nationwide

September 2016Move to the Official List of the London Stock Exchange opening up wider access to capital and more liquid secondary market. Products ranged in Olive Young Korea

18

Key Milestones

June 2016Successful Launch of Skinny Tan in the USIn ECRM (largest retail show) winning best new product award. Brand becomes No 1 brand in its category in Superdrug

October 2016Release of maiden results on the LSE. Strong revenue and profit growth over previous year

• Portfolio of quality brands with detailed marketing strategies

• Defined revenue stream and earnings from brand extensions

• Low cost and scalable business model

• Protected IP on advanced hair laser products

• Robust new product development pipeline

• Value add acquisition targets identified to integrate into the business to leverage existing and growing distribution channels

• Financial performance underpinned by an increase in revenue of over 800% £4.2m in FY 2016** (FY2015: £0.525m)

• Pace of growth expected to continue with new global markets and innovative products

19

Concluding Remarks

**Unaudited figures